TGFB1 and osteogenesis imperfecta: Recent studies showed that the murine pan‐specific TGF‐β neutralizing monoclonal antibody, 1D11, had the effect of pharmacological inhibition of TGF‐β in different mouse models, including osteogenesis imperfecta 60, chronic nephropathy 61, and asthma 30.